Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage i non-small-cell lung cancer patients with wild-type p53 tumors

Wen Pin Chien, Ruey Hong Wong, Ya Wen Cheng, Chih Yi Chen, Huei Lee

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Mouse double minute 2 (MDM2) is a negative regulator of p53. In the present study, we examined MDM2 transcriptional activity and messenger RNA (mRNA) expression in lung tumors with respect to MDM2 SNP309 genotypes and p53 mutation status, and the effects of MDM2 SNP309 genotypes and p53 mutation status on lung cancer prognosis. Methods: P53-null lung cancer cells were cotransfected with MDM2 P2 reporter construct containing the TT or GG genotype and wild-type or mutant p53 plasmids for luciferase reporter assay. Genomic DNA from 306 lung tumors and adjacent normal tissues was used to determine p53 mutation and MDM2 genotype by direct sequencing and polymerase chain reaction (PCR) restriction fragment length polymorphism. Real-time reverse-transcriptase PCR was applied to determine MDM2 mRNA levels. Overall survival was also calculated. Results: Transcriptional activity of the MDM2 promoter containing the SNP309 GG genotype was significantly lower than that containing the TT genotype in p53-null lung cancer cells cotransfected with wild-type p53 expression plasmid under mithramycin A treatment. MDM2 mRNA levels in tumors with the SNP309 TG and GG genotypes were higher than those in tumors with the TT genotype, particularly in wild-type p53 tumors. Stage I patients with MDM2 SNP309 GG also had better overall survival than TT carriers, especially wild-type p53 patients (hazard ratio = 0.34; 95% confidence interval 0.15-0.80). Similar results were not observed in late-stage patients. Conclusions: MDM2 SNP309 was associated with MDM2 transcripts, mRNA levels, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.

Original languageEnglish
Pages (from-to)1194-1202
Number of pages9
JournalAnnals of Surgical Oncology
Volume17
Issue number4
DOIs
Publication statusPublished - Apr 2010
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Messenger RNA
Survival
Genotype
Neoplasms
Lung Neoplasms
Mutation
Plasmids
Lung
Luciferases
Reverse Transcriptase Polymerase Chain Reaction
Restriction Fragment Length Polymorphisms
Real-Time Polymerase Chain Reaction
Confidence Intervals
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage i non-small-cell lung cancer patients with wild-type p53 tumors. / Chien, Wen Pin; Wong, Ruey Hong; Cheng, Ya Wen; Chen, Chih Yi; Lee, Huei.

In: Annals of Surgical Oncology, Vol. 17, No. 4, 04.2010, p. 1194-1202.

Research output: Contribution to journalArticle

Chien, Wen Pin ; Wong, Ruey Hong ; Cheng, Ya Wen ; Chen, Chih Yi ; Lee, Huei. / Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage i non-small-cell lung cancer patients with wild-type p53 tumors. In: Annals of Surgical Oncology. 2010 ; Vol. 17, No. 4. pp. 1194-1202.
@article{4a118f60db65436dafa90877dc037dfa,
title = "Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage i non-small-cell lung cancer patients with wild-type p53 tumors",
abstract = "Background: Mouse double minute 2 (MDM2) is a negative regulator of p53. In the present study, we examined MDM2 transcriptional activity and messenger RNA (mRNA) expression in lung tumors with respect to MDM2 SNP309 genotypes and p53 mutation status, and the effects of MDM2 SNP309 genotypes and p53 mutation status on lung cancer prognosis. Methods: P53-null lung cancer cells were cotransfected with MDM2 P2 reporter construct containing the TT or GG genotype and wild-type or mutant p53 plasmids for luciferase reporter assay. Genomic DNA from 306 lung tumors and adjacent normal tissues was used to determine p53 mutation and MDM2 genotype by direct sequencing and polymerase chain reaction (PCR) restriction fragment length polymorphism. Real-time reverse-transcriptase PCR was applied to determine MDM2 mRNA levels. Overall survival was also calculated. Results: Transcriptional activity of the MDM2 promoter containing the SNP309 GG genotype was significantly lower than that containing the TT genotype in p53-null lung cancer cells cotransfected with wild-type p53 expression plasmid under mithramycin A treatment. MDM2 mRNA levels in tumors with the SNP309 TG and GG genotypes were higher than those in tumors with the TT genotype, particularly in wild-type p53 tumors. Stage I patients with MDM2 SNP309 GG also had better overall survival than TT carriers, especially wild-type p53 patients (hazard ratio = 0.34; 95{\%} confidence interval 0.15-0.80). Similar results were not observed in late-stage patients. Conclusions: MDM2 SNP309 was associated with MDM2 transcripts, mRNA levels, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.",
author = "Chien, {Wen Pin} and Wong, {Ruey Hong} and Cheng, {Ya Wen} and Chen, {Chih Yi} and Huei Lee",
year = "2010",
month = "4",
doi = "10.1245/s10434-009-0853-2",
language = "English",
volume = "17",
pages = "1194--1202",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage i non-small-cell lung cancer patients with wild-type p53 tumors

AU - Chien, Wen Pin

AU - Wong, Ruey Hong

AU - Cheng, Ya Wen

AU - Chen, Chih Yi

AU - Lee, Huei

PY - 2010/4

Y1 - 2010/4

N2 - Background: Mouse double minute 2 (MDM2) is a negative regulator of p53. In the present study, we examined MDM2 transcriptional activity and messenger RNA (mRNA) expression in lung tumors with respect to MDM2 SNP309 genotypes and p53 mutation status, and the effects of MDM2 SNP309 genotypes and p53 mutation status on lung cancer prognosis. Methods: P53-null lung cancer cells were cotransfected with MDM2 P2 reporter construct containing the TT or GG genotype and wild-type or mutant p53 plasmids for luciferase reporter assay. Genomic DNA from 306 lung tumors and adjacent normal tissues was used to determine p53 mutation and MDM2 genotype by direct sequencing and polymerase chain reaction (PCR) restriction fragment length polymorphism. Real-time reverse-transcriptase PCR was applied to determine MDM2 mRNA levels. Overall survival was also calculated. Results: Transcriptional activity of the MDM2 promoter containing the SNP309 GG genotype was significantly lower than that containing the TT genotype in p53-null lung cancer cells cotransfected with wild-type p53 expression plasmid under mithramycin A treatment. MDM2 mRNA levels in tumors with the SNP309 TG and GG genotypes were higher than those in tumors with the TT genotype, particularly in wild-type p53 tumors. Stage I patients with MDM2 SNP309 GG also had better overall survival than TT carriers, especially wild-type p53 patients (hazard ratio = 0.34; 95% confidence interval 0.15-0.80). Similar results were not observed in late-stage patients. Conclusions: MDM2 SNP309 was associated with MDM2 transcripts, mRNA levels, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.

AB - Background: Mouse double minute 2 (MDM2) is a negative regulator of p53. In the present study, we examined MDM2 transcriptional activity and messenger RNA (mRNA) expression in lung tumors with respect to MDM2 SNP309 genotypes and p53 mutation status, and the effects of MDM2 SNP309 genotypes and p53 mutation status on lung cancer prognosis. Methods: P53-null lung cancer cells were cotransfected with MDM2 P2 reporter construct containing the TT or GG genotype and wild-type or mutant p53 plasmids for luciferase reporter assay. Genomic DNA from 306 lung tumors and adjacent normal tissues was used to determine p53 mutation and MDM2 genotype by direct sequencing and polymerase chain reaction (PCR) restriction fragment length polymorphism. Real-time reverse-transcriptase PCR was applied to determine MDM2 mRNA levels. Overall survival was also calculated. Results: Transcriptional activity of the MDM2 promoter containing the SNP309 GG genotype was significantly lower than that containing the TT genotype in p53-null lung cancer cells cotransfected with wild-type p53 expression plasmid under mithramycin A treatment. MDM2 mRNA levels in tumors with the SNP309 TG and GG genotypes were higher than those in tumors with the TT genotype, particularly in wild-type p53 tumors. Stage I patients with MDM2 SNP309 GG also had better overall survival than TT carriers, especially wild-type p53 patients (hazard ratio = 0.34; 95% confidence interval 0.15-0.80). Similar results were not observed in late-stage patients. Conclusions: MDM2 SNP309 was associated with MDM2 transcripts, mRNA levels, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.

UR - http://www.scopus.com/inward/record.url?scp=77952090036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952090036&partnerID=8YFLogxK

U2 - 10.1245/s10434-009-0853-2

DO - 10.1245/s10434-009-0853-2

M3 - Article

C2 - 19941079

AN - SCOPUS:77952090036

VL - 17

SP - 1194

EP - 1202

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -